Gelatinase activity in synovial fluid and synovium obtained from healthy and osteoarthritic joints of dogs

American Journal of Veterinary Research

Volumn 64, Issue 10, 2003, Pages 1225-1233

  Volk, Susan W ^a   Kapatkin, Amy S ^a   Haskins, Mark E ^a   Walton, Raquel M ^a   D'Angelo, Marina ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN; ENZYME ANTIBODY; GELATIN; GELATINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG DISEASE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SUBSTRATE; ENZYME SYNTHESIS; FEMALE; LYSOSOME STORAGE DISEASE; MALE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; OSTEOARTHRITIS; QUANTITATIVE ANALYSIS; SYNOVIAL FLUID; SYNOVIOCYTE; SYNOVIUM; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; DOG DISEASES; DOGS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUCOPOLYSACCHARIDOSIS VII; OSTEOARTHRITIS; REFERENCE VALUES; SYNOVIAL FLUID; SYNOVIAL MEMBRANE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0141990588     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2003.64.1225     Document Type: Article

References (47)

1. Lipowitz AJ, Newton CD. Degenerative joint disease and traumatic arthritis. In: Newton CD, Nunamaker DM, eds. Textbook of small animal orthopaedics. Philadelphia: JB Lippincott Co, 1985;1029-1045.
2. Cawston TE, Billington C. Metalloproteinases in the rheumatic diseases. J Pathol 1996;180:115-117.
3. Poole AR, Alini M, Hollander AH. Chondrocytes and cartilage destruction. In: Henderson B, Edwards J, Pettipher R, eds. Mechanisms and models in rheumatoid arthritis. London: Academic Press Inc, 1995;163-204.
4. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases. Arthritis Rheum 2002; 46:13-20.
5. Egebald M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev 2002;2:161-174.
6. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 1999;7:371-373.
7. Hedbom E, Häuselmann HJ. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci 2002; 59:45-53.
8. Yoshihara Y, Nakamura H, Obata K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59:455-461.
9. Kapatkin AS, Volk SW, Keith DG, et al. Elbow dysplasia in a Basset Hound: a case report following serial radiographic, computed tomographic and arthroscopic findings. Vet Comp Orthop Traumatol 2003;16:11-15.
10. Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001;81:1319-1328.
11. Haskins M, Giger U. Lysosomal storage disease. Clinical biochemistry of domestic animals. 5th ed. New York: Academic Press Inc, 1997;741-760.
12. Ponder KP, Melniczek JR, Xu L, et al. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci U S A 2002;99:13102-13107.
13. Sarment DP, Korostoff J, D'Angelo M, et al. In situ localization and characterization of active proteinases in chronically inflamed and healthy human gingival tissues. J Periodontol 1999;70:1303-1312.
14. Gilbert SJ, Wotton PR, Tarlton JF, et al. Increased expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy. Cardiovasc Res 1997;34:377-383.
15. Chu P, Salamonsen LA, Lee CS, et al. Matrix metalloproteinases (MMPs) in the endometrium of bitches. Reproduction 2002; 123:467-477.
16. Yokota H, Kumata T, Taketaba S, et al. High expression of 92 kDa type IV collagenase (matrix metalloproteinase-9) in canine mammary adenocarcinoma. Bioch1im Biophys Acta 2001;1568:7-12.
17. Bergman RL, Inzana KD, Inzana TJ. Characterization of matrix metalloproteinase-2 and -9 in cerebrospinal fluid of clinically normal dogs. Am J Vet Res 2002;63:1359-1362.
18. Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 2000;61:111-114.
19. Tsuchiya K, Maloney WJ, Vu T, et al. Osteoarthritis: differential expression of matrix metalloproteinase-9 mRNA in nonfibrillated and fibrillated cartilage. J Bone Joint Surg 1997;15:94-100.
20. Tsuchiya K, Maloney WJ, Vu T, et al. RT-PCR analysis of MMP-9 expression in human articular cartilage chondrocytes and synovial fluid cells. Biotech Histochem 1996;71:208-213.
21. Jovanovic D, Caron JP, Martel-Pelletier J, et al. The therapeutic effects of Tenidap in canine experimental osteoarthritis: relationship with biochemical markers. J Rheumatol 1997;24:916-925.
22. Maiotti M, Monteleone G, Tarantino U, et al. Correlation between osteoarthritic cartilage damage and levels of proteinases and proteinase inhibitors in synovial fluid from the knee joint. Arthroscopy 2000;16:522-526.
23. Shapiro SD, Fliszar CJ, Broekelmann TH, et al. Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem 1995;270:6351-6356.
24. Mohtai M, Smith RL, Schurman DJ, et al. Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 1993;92:179-185.
25. Coughlan AR, Robertson DHL, Bennett D, et al. Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis. Vet Rec 1998; 143:219-223.
26. Trumble TN, Trotter GW, Oxford JR, et al. Synovial fluid gelatinase concentrations and matrix metalloproteinase and cytokine expression in naturally occurring joint disease in horses. Am J Vet Res 2001;62:1467-1477.
27. Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-697.
28. Meikle MC, Bord S, Hembry RM, et al. The synthesis of collagenase, gelatinase-A (72kDa) and -B (95kDa), and TIMP-1 and -2 by human osteoblasts from normal and arthritic bone. Bone 1995; 17:255-260.
29. Clegg PD, Burke RM, Coughlan AR, et al. Characterisation of equine matrix metalloproteinase 2 and 9; and identification of the cellular sources of these enzyme in joints. Equine Vet J 1997; 29:335-342.
30. Su S, Grover J, Roughley PJ, et al. Expression of the tissue inhibitor of metalloproteinases (TIMP) gene family in normal and osteoarthritic joints. Rheumatol Int 1999;18:183-191.
31. Goldberg GI, Strongin A, Collier IE, et al. Interaction of 92 kDa type IV collagenase with tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992; 267:4583-4591.
32. Hembry RM, Bagga MR, Reynolds JJ, et al. Immunolocalization studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1995;54:25-32.
33. Grillet B, Dequeker J, Paemen L, et al. Gelatinase B in chronic synovitis: immunolocalization with a monoclonal antibody Br J Rheumatol 1997;36:744-747.
34. Ahrens D, Koch AE, Pope RM, et al. Expression of matrix metalloproteinases 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996;39:1576-1587.
35. Gruber BL, Sorbi D, French DL, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 1996; 78:161-171.
36. Fridman R, Toth M, Pena D, et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55:2548-2555.
37. Sang Q-X, Birkedal-Hansen H, Van Wart HE. Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim Biophys Acta 1995;1251:99-108.
38. Brama PAJ, TeKoppele JM, Beekman B, et al. Matrix metalloproteinase activity in equine synovial fluid: influence of age, osteoarthritis, and osteochondrosis. Ann Rheum Dis 1998;57:697-699.
39. Lindhorst E, Guilak TPVF, Wang H, et al. Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis. J Orthop Res 2000;18:269-280.
40. Panula HE, Lohmander LS, Rönkkö S, et al. Elevated levels of synovial fluid PLA2, stromelysin (MMP-3) and TIMP in early osteoarthrosis after tibial valgus osteotomy in young beagle dogs. Acta Orthop Scand 1998;69:152-158.
41. Fernandes JC, Caron JP, Martel-Pelletier J, et al. Effects of Tenidap on the progression of osteoarthritic lesions in a canine experimental model. Arthritis Rheum 1997;40:284-294.
42. Pickvance EA, Oegema TR Jr, Thompson RC Jr. Immunolocalization of selected cytokines and proteinases in canine articular cartilage after transarticular loading. J Orthop Res 1993; 11:313-323.
43. Fernandes JC, Martel-Pelletier J, Lascau-Coman V, et al. Collagenase-1 and Collagenase-3 synthesis in normal and early experimental osteoarthritic canine cartilage: an immunohistochemical study. J Rheumatol 1998;25:1585-1594.
44. Smith GN Jr, Mickler EA, Hasty KA, et al. Specificity of inhibition of matrix metalloproteinase activity by doxycycline. Arthritis Rheum 2000;42:1140-1146.
45. Pelletier JP, Lajeunesse D, Jovanovic DV, et al. Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. J Rheumatol 2000;27:2893-2902.
46. Dvorak LD, Cook JL, Kreeger JM, et al. Effects of carprofen and dexamethasone on canine chondrocytes in a three-dimensional culture model of osteoarthritis. Am J Vet Res 2002;63:1363-1369.
47. Clegg PD, Coughlan AR, Riggs CM, et al. Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine Vet J 1997; 29:343-348.